Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 11/20 | 0.45 |
| ▸ | CCR2 | P41597 | 2/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | CCR4 | P51679 | 1/20 | 0.45 |
| ▸ | RARB | P10826 | 2/20 | 0.43 |
| ▸ | RARA | P10276 | 1/20 | 0.43 |
| ▸ | CCR7 | P32248 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6342677 | 0.93 | MEN1 (0.43) | CCR5CCR2CCR3CCR4CCR7 | |
| SCHEMBL6340409 | 0.92 | MEN1 (0.42) | CCR5CCR2CCR3CCR4CCR7 | |
| SCHEMBL6341045 | 0.92 | MEN1 (0.43) | CCR5CCR2CCR3CCR4MAPT | |
| SCHEMBL5655925 | 0.91 | RARB (0.49) | CCR5CCR2CCR3CCR4RARB | |
| SCHEMBL6339035 | 0.88 | MEN1 (0.51) | MAPTMEN1KMT2APOLBHTT | |
| SCHEMBL6343228 | 0.87 | MEN1 (0.41) | CCR5CCR2CCR3CCR4CCR7 | |
| SCHEMBL6342839 | 0.86 | MEN1 (0.39) | CCR5CCR2CCR3CCR4MAPT | |
| SCHEMBL6350067 | 0.85 | CCR5 (0.45) | CCR5CCR2CCR3CCR4RARB | |
| SCHEMBL6341921 | 0.85 | CCR5 (0.48) | CCR5CCR2CCR3CCR4RARB | |
| SCHEMBL6349959 | 0.84 | CCR5 (0.45) | CCR5CCR2CCR3CCR4RARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262185-B2 | Benzazepine derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422228-A1 | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | CYP1B1, CYP1A1, CYP2E1 | CCR5 2363/4885CCR2 1368/4885CCR3 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.